Curaderm BEC5 cream, derived from Solasodine Glycosides, selectively targets non-melanoma skin cancer cells (BCC and SCC), induces apoptosis, and promotes gradual natural skin regeneration as a non-invasive treatment option. It is not effective for melanoma and is best considered for small, localized non-melanoma lesions under professional guidance.
Salicinium is a naturally derived glycome that is claimed to selectively disrupt fermenting cells by interfering with the NAD+ cycle, making these cells vulnerable and more detectable by the immune system. By reactivating macrophages and NK cells and halting Nagalase, it is promoted as a non-toxic immune-supporting compound with potential benefits for cellular health.
Curaderm BEC5 is a topical cream containing Solasodine Glycosides that selectively targets abnormal skin cells, triggers apoptosis, and supports natural skin regeneration as a non-invasive alternative to surgeries. Clinical studies and patient experiences suggest it can reduce abnormal growths with minimal side effects when used correctly, though a healthcare professional should be consulted.
Curaderm is a plant-based topical cream (BEC5) that targets abnormal skin cells and induces apoptosis, potentially aiding early-stage or superficial squamous cell carcinoma (SCC) under medical supervision. However, it’s effectiveness for invasive SCC is not we’ll established, and standard medical treatments are recommended for deeper or spreading disease.
